FleetPulse | $11,000,000 | (May 10, 2024)
ArkeaBio™ | $26,500,000 | (May 10, 2024)
Bluejay Therapeutics | $182,000,000 | (May 10, 2024)
Causaly
United Kingdom
- London, England
- 14/07/2023
- Series B
- $60,000,000
Our mission at Causaly is to redefine the boundaries of human discovery by harnessing transformative AI technologies. Founded in 2018, Causaly’s unique AI platform is a powerful catalyst for the modern Life Science research organization, reshaping how data is found, analyzed and applied in critical decision-making processes in drug discovery and development.
Supporting a broad range of complex knowledge workflows, our platform accelerates the journey from bench research and laboratory insights to the launch of life-changing therapies.
- Industry Business Intelligence Platforms
- Website https://www.causaly.com/
- LinkedIn https://www.linkedin.com/company/causaly/
Related People
Yiannis KiachopoulosCo Founder
United Kingdom -
London Area
In Causaly we amplify human cognitive abilities to expand the boundaries of discovery towards making the best decisions in Biomedicine.
To achieve this, we are teaching computers to read all knowledge ever published and develop an interface that allows humans to answer questions they can’t ask anywhere else.
CoverTree | $13,000,000 | (May 10, 2024)
Li Industries | $36,000,000 | (May 10, 2024)
Archive Intel | $1,000,000 | (May 10, 2024)
Little Sparrows Technologies | $3,000,000 | (May 10, 2024)
Triomics | $15,000,000 | (May 10, 2024)
Altera | $9,000,000 | (May 10, 2024)
Electricity Maps | $5,390,775 | (May 10, 2024)
Sift Healthcare | $20,000,000 | (May 10, 2024)
Aardvark Therapeutics | $85,000,000 | (May 10, 2024)
Chip City | $7,500,000 | (May 10, 2024)